THE LEUKEMIA & LYMPHOMA SOCIETY launched a program to fund research projects focused on myeloid diseases, such as myelodysplastic syndromes and myeloproliferative neoplasms, both of which can progress to acute myeloid leukemia.
Janssen Research & Development is co-sponsoring the program, and together the organizations have committed to providing a combined $1.7 million for the initiative.
LLS is issuing a request for proposals with the intent of funding research projects at $400,000 each for a period of three years. The grants will be administered as part of LLS’s new “Transforming Cures Initiative—Intercepting Progression to Advanced Myeloid Blood Cancers.”
Researchers who apply for these grants will focus on identifying the molecular drivers that cause progression to leukemia and/or working toward development of treatment strategies for early interception of the disease. More information is available at www.lls.org/tci.
